Octant is a synthetic-biology drug discovery company designing multi-target drug leads for multifactorial diseases. Octant engineers biology, using living cells as high-throughput data networks to map, measure and model compound reactions against GPCRs and ultimately, the entire universe of human receptors. Octant's novel polypharmacology discovery engine generates multi-receptor pathway data and predictive insights to inform rational drug design with unprecedented speed, scale and precision.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/20/20 | $30,000,000 | Series A |
Allen & Company SV Angel | undisclosed |
| 04/21/22 | $80,000,000 | Series B |
50 Years VC Allen & Company Andreessen Horowitz Bristol-Myers Squibb Catalio Capital Management  | undisclosed |
